Creative Planning
NBIX icon

Creative Planning’s Neurocrine Biosciences NBIX Stock Holding History

Creative Planning’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-100
Closed -$1K – 2226
2020
Q2 		$1K Buy
+100
New +$11.1K ﹤0.01% 1996

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Creative Planning's NBIX Position: Q2 2026 in Review

Creative Planning increased its Neurocrine Biosciences (NBIX) stake by 12% in Q2 2026, buying an estimated $1.25M and bringing the position to 76,818 shares worth $12.9M. The position accounts for 0.01% of the portfolio, ranked #712.

Creative Planning first reported a position in NBIX in Q2 2013 and has held it in 50 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Creative Planning held 76,818 shares of Neurocrine Biosciences worth $12.9M as of Q2 2026.
  • Creative Planning bought 8,431 Neurocrine Biosciences shares in Q2 2026, an estimated $1.25M.
  • Neurocrine Biosciences made up 0.01% of Creative Planning's portfolio in Q2 2026, its #712 holding.
  • Creative Planning first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 50 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.